TSE:4523Pharmaceuticals
How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings
In recent weeks, Eisai and its partners reported multiple developments, including UK regulators accepting marketing applications for insomnia drug lemborexant and ROS1+ lung cancer therapy taletrectinib, alongside extensive new clinical and real-world data on Alzheimer’s treatment lecanemab (Leqembi) at the 2026 Alzheimer’s Association International Conference.
These updates, together with the extension of Eisai’s neuroscience collaboration with University College London to 2030, highlight...